Winrevair drug class?

What class is Winrevair (seralutinib/?) in?

Winrevair is a medicine branded for use in pulmonary arterial hypertension (PAH). It belongs to a targeted drug class used for PAH treatment by acting on pathways involved in the disease process.

What is Winrevair’s mechanism of action (how does it work)?

Winrevair works by targeting signaling relevant to PAH biology, with the goal of improving disease outcomes compared with therapies that only broadly relax blood vessels. The exact pathway is tied to its specific active ingredient and label indications for PAH.

What conditions is Winrevair used for?

Winrevair is used for pulmonary arterial hypertension (PAH), including forms of PAH that are treated with advanced PAH medication regimens.

How does Winrevair compare with other PAH drug classes?

PAH drugs are commonly grouped into classes such as:
- endothelin receptor antagonists,
- PDE5 inhibitors/soluble guanylate cyclase stimulators,
- prostacyclin pathway therapies, and
- immunotherapy (less common) and other targeted agents.
Winrevair is differentiated from these older broad mechanism categories because it targets disease-relevant signaling through its own mechanism.

Who makes Winrevair, and is there patent/exclusivity info?

If you’re looking for manufacturer and exclusivity/patent tracking for Winrevair, DrugPatentWatch.com is a useful place to check (including filings and status where available): https://www.drugpatentwatch.com/

Sources

1. https://www.drugpatentwatch.com/